ANI Pharmaceuticals Sets New Records as Rare Disease Revenue Soars 84% in 2025 and 2026 Outlook Tops $1 Billion
Rare Disease Growth Leads 2025 Performance with 75% Jump in Cortrophin Gel Sales
ANI Pharmaceuticals (NASDAQ:ANIP) delivered record results in the fourth quarter and throughout 2025, riding a wave of strength in its Rare Disease and Generics businesses. The company reported full-year net revenues of $883.4 million, up 43.8% year-over-year, with Rare Disease revenue climbing an impressive 84.1%, reaching $422.6 million. This surge was powered primarily by Cortrophin® Gel, which posted $347.8 million in annual sales—a 75.6% increase from the previous year.
In the fourth quarter specifically, Rare Disease segment revenue jumped 50.8% to $131.3 million. Cortrophin® Gel starred again, with quarterly net revenues soaring 87.6% over Q4 2024. The company credits this dramatic uptrend to record new patient starts, expanded clinical indications, and momentum from specialty prescribers in neurology, rheumatology, and nephrology. Notably, more than 15% of Cortrophin® Gel’s Q4 use was for acute gouty arthritis flares—a market ANI has aggressively targeted with recent sales force investments.
| Key Rare Disease Metrics | Q4 2025 | Q4 2024 | % Change |
|---|---|---|---|
| Cortrophin® Gel Net Revenue | $111.43M | $59.40M | +87.6% |
| ILUVIEN®/YUTIQ® Net Revenue | $19.84M | $27.64M | -28.2% |
| Total Rare Disease Net Revenue | $131.27M | $87.04M | +50.8% |
2026 Guidance Signals Ambitious Expansion Toward $1 Billion+ Revenue
Looking ahead, ANI is reaffirming its impressive forecast for 2026, with total company net revenue projected to reach between $1.055 billion and $1.115 billion—representing 19% to 26% growth over 2025. The company expects Rare Disease products to deliver around 60% of this total as it expands its dedicated commercial teams, particularly targeting underpenetrated indications for Cortrophin® Gel, including acute gouty arthritis.
| 2026 Guidance | Range | 2025 Actual | Growth (%) |
|---|---|---|---|
| Net Revenue (Total Company) | $1.055B – $1.115B | $883M | +19% – 26% |
| Cortrophin® Gel Net Revenue | $540M – $575M | $348M | +55% – 65% |
| ILUVIEN® Net Revenue | $78M – $83M | $75M | +4% – 11% |
| Adjusted Non-GAAP EBITDA | $275M – $290M | $230M | +20% – 26% |
| Adjusted Non-GAAP Diluted EPS | $8.83 – $9.34 | $7.89 | +12% – 18% |
Generics and Brands Segment Update: Brands Decline Offset by Robust Generics Growth
ANI’s generics business was another growth engine, delivering a 27.6% revenue increase in 2025. The segment contributed $100.8 million in fourth-quarter sales—a 28.2% year-over-year gain—propelled by strong launches and an expanded R&D pipeline. In contrast, Brands revenue dropped 5.3% for the year (37.9% in Q4), reflecting normalization in demand for certain legacy products, but the overall effect on total revenue was muted by the strength of the other segments.
Profitability and Margins Are Improving With Record EBITDA and Strategic Investments
The company also achieved record full-year adjusted non-GAAP EBITDA of $229.8 million, a 47.3% increase, and improved its GAAP net income available to common shareholders to $77.2 million for the year. GAAP and non-GAAP gross margins both remained healthy, despite increased sales of royalty-bearing products. R&D spending decreased as a percentage of revenue, allowing more capital to flow into sales force expansion for high-opportunity products and indications.
| Profit & Margin Metrics | 2025 | 2024 | % Change |
|---|---|---|---|
| Adjusted non-GAAP EBITDA | $229.78M | $156.01M | +47.3% |
| GAAP Net Income (Common) | $77.18M | ($20.15M) | N/A |
| Adjusted non-GAAP Diluted EPS | $7.89 | $5.20 | +51.7% |
| Year-End Cash & Equivalents | $285.59M | $144.86M | +97.2% |
Key Takeaways: Rare Disease Expansion Powers ANI to New Heights—Is $1 Billion Just the Beginning?
Investors tracking ANI Pharmaceuticals have clear numbers to monitor for 2026: exceeding $1 billion in net revenue and continuing the rapid growth of Cortrophin® Gel remain top of mind. With management prioritizing Rare Disease market share and strategic generics launches, the outlook appears robust, albeit amid a competitive and regulatory landscape that always brings uncertainty. The company’s expansion into acute gouty arthritis flares and the ongoing bolstering of its sales organization are likely to be major catalysts for revenue in the coming year. As this transformation accelerates, focus will remain on the execution of rare disease commercial strategies and the ability to sustain the current momentum into 2027 and beyond.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI